NCT06087276View on ClinicalTrials.gov

Essential 3 - Decentralized, Phase 3 Study Evaluating the Safety and Efficacy of Ulixacaltamide in Essential Tremor (ET)

PHASE3Enrolling by invitationINTERVENTIONAL
Enrollment

1,000

Participants

Timeline

Start Date

November 2, 2023

Primary Completion Date

September 30, 2025

Study Completion Date

December 31, 2026

Conditions
Essential Tremor
Interventions
DRUG

60 mg ulixacaltamide

Once daily oral treatment with titration

DRUG

Placebo

Once daily oral treatment

Trial Locations (1)

26508

United BioSource LLC, Morgantown

Sponsors
All Listed Sponsors
lead

Praxis Precision Medicines

INDUSTRY